September 9th 2025
Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
SGLT2 Inhibitor Empagliflozin Found Safe, Effective for HFpEF in Landmark EMPORER-Preserved Trial
July 7th 2021Empagliflozin, already indicated to improve outcomes in patients with HFrEF, reduced risk of a composite of CV death or hospitalization for HF in adults HFpEF, marking a potential therapeutic milestone.